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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not maternal
buprenorphine use during pregnancy is effective in preventing neonatal abstinence syndrome
(NAS).
STUDY DESIGN: Review of three English language primary studies published in 2005, 2006
and 2008.
DATA SOURCES: Two randomized, double blind (with flexible dosing) trials and one case
series comparing methadone maintenance and buprenorphine maintenance during pregnancy
were found using Ovid MEDLINE and CINAHL databases.
OUTCOME MEASURED: Incidence of neonates requiring treatment for NAS and amount of
medication used, total length of hospital stay and peak NAS scores using the Finnegan Scale and
a modified 19 item Finnegan Scale. The Finnegan Scale assess infants for the most common
signs and symptoms of neonatal withdrawal including: High pitched cry, restlessness,
hyperactive moro reflex, tremors, increased muscle tone, excoriation, myoclonic jerks,
convulsions, sweating, fever, yawning, mottling, nasal stuffiness, sneezing, nasal flaring,
increased respiratory rate, excessive sucking, poor feeding, regurgitation/vomiting, lose/watery
stools.
RESULTS: The two RCTs included in this review did not find maternal buprenorphine use to be
effective in preventing NAS. The case series included did find a significant relationship between
maternal buprenorphine use and a reduction in NAS symptoms.
CONCLUSIONS: The results of the two RCTs demonstrate that maternal buprenorphine use is
not effective in preventing NAS symptoms. The case series did find a significant relationship,
however because of the nature of the study (case series) the results must be interpreted with
caution and additional RCTs are needed to evaluate the effectiveness of maternal buprenorphine
use and NAS.
KEY WORDS: Neonatal abstinence syndrome, withdrawal, buprenorphine, methadone,
pregnancy.
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INTRODUCTION
Illicit drug use among pregnant women is on the rise, resulting in over 225,000 infants in
the past year to be exposed to illegal substances prenatally1. Neonates exposed to illicit drugs
are at greater risk of developing neonatal abstinence syndrome (NAS) as an astounding 50%95% of infants exposed to heroin in utero will exhibit signs and symptoms of NAS2. While NAS
is becoming more prevalent, there remains controversy regarding the most effective way to
prevent and treat this illness.
Approximately 5.2% of pregnant women and 9.2% of non-pregnant women report pastmonth illicit drug use1 making maternal substance abuse and NAS an all too relevant topic in
medicine today. The prevalence of opioid use during pregnancy ranges from 1-21% of women2.
While an exact cost of treating NAS has not been identified, neonatal withdrawal results in
longer hospital stays and ultimately increased costs as 60-80% of all infants exposed to
methadone will present with some symptoms of NAS6.
Neonatal withdrawal can occur when a fetus is exposed to a variety of illicit drugs or
medications such as opiates, tobacco, alcohol and sedatives. Signs and symptoms of NAS are
generally seen within 2-3 days of birth, but may not present for up to one month1. Infants are
evaluated using the Finnegan Scale, a standardized scoring system that identifies 21 signs and
symptoms of withdrawal, such as decreased sleep, tremors, excessive suck, sweating and loose
stools3,4,5.
NAS is generally treated using diluted tincture of opium (DTO)1, however methadone
and morphine are alternatives. In addition to DTO, oral Phenobarbital is often used adjunctively.
While these treatments are effective, more information is needed regarding the prevention of
NAS. Methadone is the only recommended treatment for opiate dependence in pregnant women,
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however over half of methadone exposed infants require treatment for NAS1. Buprenorphine, an
opioid substitute that has both mixed agonist and antagonist properties may provide an
alternative to methadone in pregnant patients. Because buprenorphine has high opioid receptor
affinity and low intrinsic activity adults experience fewer signs and symptoms of withdrawal
upon discontinuation, it is theorized that infants exposed to buprenorphine in utero may
experience fewer signs and symptoms of withdrawal when compared to methadone.1.
OBJECTIVE
The objective of this systematic review is to determine whether or not maternal
buprenorphine use during pregnancy is effective in preventing neonatal abstinence syndrome.
METHODS
Included in this analysis were two randomized controlled trials (RCTs) and a case series,
all of which compared maternal buprenorphine use to methadone. The criteria used to select
each study included pregnant women who were at least 18 years of age3 or between the ages of
21-434,5 that met the DSM-IV criteria for opioid dependence. The intervention used was
sublingual buprenorphine 4-24 mg. Comparison to this intervention was oral methadone HCL
20-100 mg. To assess outcomes a variety of methods were used including the Finnegan Scale
and modified Finnegan Scale to assess for signs and symptoms of NAS, need for pharmacologic
intervention and length of neonatal hospital stay.
A detailed inquiry was performed by the author using the search engines OVID Medline
and CINAHL. The key words “Neonatal abstinence syndrome”, “Buprenorphine” and
“Pregnancy” were used in combination to search for articles. The articles chosen were published
in English and in peer-reviewed journals from 2005-2008. Articles were selected based on their
relevance and the importance of outcomes to the patient (Patient Oriented Evidence that Matters,
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or POEMS). Studies included in this review were two randomized, prospective, controlled,
double blind/double dummy and one case series, all of which included patient oriented
outcomes. Table 1 includes the demographics of the included studies. Studies that were
excluded included those that used combination treatment with buprenorphine or methadone and
those with participants under the age of 18. The statistics utilized in the studies were relative risk
reduction (RRR), absolute risk reduction (ARR), numbers needed to treat (NNT) and p-value.
OUTCOMES MEASURED
The primary outcome measured in all three studies was the severity of neonatal
withdrawal using either the Finnegan scale3,6 or modified 19-Item Finnegan scale5. The
Finnegan scale is a 21 item standardized scoring system that assess for signs and symptoms of
opioid withdrawal in neonates4. The Finnegan scale includes the following signs and symptoms
of withdrawal: Increased/high pitched cry, decreased sleep, hyperactive moro-reflex, tremors
(disturbed and undisturbed), increased muscle tone, excoriation, myoclonic jerks, convulsions,
mottling, nasal stuffiness, nasal flaring, sweating, fever, increased respiratory rate, excessive
suck, regurgitation/vomiting, poor feeding and loose/watery stools4. Jones et al utilized a
modified Finnegan scale that did not include myoclonic jerks, mottling and excessive suck as
part of the evaluation5. Other outcomes measured included the number of infants requiring
medication management and the total days of neonatal hospital stay 5,6. In addition Jones et al
included total amount of morphine needed to treat NAS symptoms5.
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Table 1: Demographics of included studies
Study
Jones4,
2005

Type
Double
blind with
flexible
dosing
RCT

Fischer3, Double
2006
blind with
flexible
dosing
RCT

Kakko5,
2008

#
Age
pts
30 21-40

Inclusion
Criteria
Gestational age
of 16-30 wks;
opioid
dependence
with request
for
maintenance
therapy; recent
opioid use;
opiate positive
urine

18

Age ≥ Opioid
18
dependence;
gestational age
of 24-29 wks;
opioid positive
urine, but neg
for benzos and
methadone;
negative
ETOH breath
test

Case series 65

Age ≥ Buprenorphine
18
arm: one year
of documented
opioid
dependence;
methadone
arm: four years
of documented
opioid
dependence

Exclusion
W/
Criteria
D
Urine positive
10
for
undocumented
methadone;
ETOH
abuse/dependen
ce; use of
benzos; serious
concurrent
medical illness;
pre-term labor;
fetal
malformation;
HIV +; sickle
cell trait
Severe somatic 4
or other
psychiatric
distress; high
risk pregnancies

Less than one
year of
documented
opioid use
(buprenorphine
arm); less than
four years of
documented
opioid
dependence
(methadone
arm)

0

Interventions
Randomized to
receive SL
buprenorphine
HCL (4-24
mg) or
methadone
HCL (20-100
mg)

Randomized to
receive
buprenorphine
(8-24 mg) or
methadone
(40-100 mg)

Buprenorphine
maintenance to
methadone
maintenance
during
pregnancy
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RESULTS
The studies performed by Fischer et al and Jones el al were RCTs that utilized double
blind, double dummy with flexible dosing methods in which the neonates were observed inpatient under blinded conditions regarding the mothers treatment. Kakko et al utilized data that
was analyzed retrospectively, as it was a case series. Results reported by Fischer et al were
presented as continuous data that could not be converted to dichotomous data, where as results
reported by Jones et al and Kakko et al were presented in dichotomous format.
Fischer et al did not report sufficient information to convert data to dichotomous format.
The authors did report the following; the mean duration of treatment for neonates exposed to
buprenorphine was 4.8 days and neonates exposed to methadone was 5.3 days, with a reported pvalue of 0.766 (Table 2). Additionally, infants exposed to methadone required treatment for
NAS approximately 12 hours before those exposed to buprenorphine, with a reported p-value of
0.537. The amount of medication needed to treat symptoms of NAS did not vary widely as those
exposed to buprenorphine required 2.00 mg (± 2.00) of morphine where as those exposed to
methadone required 2.71 mg (±1.68) of morphine, with a reported p-value of 0.640 (Table 2).
The authors also found that neonates from mothers with high rates of cigarette use (more than 10
cigarettes per day) had higher Finnegan scores than those who smoked less than 10 cigarettes per
day. At the time of delivery the mean dose of buprenorphine given to subjects during pregnancy
was 13.5 mg and the mean dose of methadone was 47.5 mg (Table 4).
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Table 2: Reported data by Fischer et al.
Data Reported
Mean duration of
treatment (days)
Amount of medication
needed to treat (mg of
morphine)

Buprenorphine
group
4.8 days

Methadone group

p-value

5.3 days

0.766

2.00 mg (± 2.00)

2.71 mg (± 1.68)

0.640

Jones et al reported that 20% of neonates exposed to buprenorphine required treatment
for NAS whereas 45% of infants exposed to methadone required treatment, with a reported pvalue of 0.23. The RRR and ARR were calculated to be 56% and 25.5% respectively. NNT was
-4, therefore for every 4 patients exposed to buprenorphine in utero there was one fewer
incidence of NAS compared to the group exposed to methadone (Table 3). At the time of
delivery the average dose of buprenorphine given to subjects during the pregnancy was 18.7 mg
and the average dose of methadone was 79.1 mg (Table 4).
Kakko et al reported that 40.4% of neonates exposed to buprenorphine exhibited
symptoms of NAS, whereas 77.8% of those exposed to methadone did, with a calculated p-value
of 0.0008. RRR and ARR were calculated to be 48% and 37.4% respectively. NNT was -3,
therefore for every 3 patients exposed to buprenorphine there was one fewer incidence of NAS
than in the group exposed to methadone (Table 3). Kakko et al also reported that 14.9% of
infants exposed to buprenorphine required treatment for NAS symptoms, where as 52.8% of
those exposed to methadone did, with a p-value of 0.0004. Additionally the total hospital stay
was significantly longer in infants exposed to methadone (19.7 ± 18.8 days) compared to infants
exposed to buprenorphine (9.4 ± 8.4 days), with a reported p-value of 0.0009. At the time of
birth, the mean amount of buprenorphine given to subjects during the pregnancy was 15.4 mg (±
6.4) and the mean amount of morphine was 71.3 mg (± 27.3) (Table 4).
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Table 3-Efficacy of buprenorphine in prevention of NAS (Jones et al & Kakko et al)
Study

CER

EER

RRR

ARR

p-value

NNT

Jones4

45.5%

20%

-56%

-25.5%

0.23

-4

Kakko5

77.8%

40.4%

-48%

-37.4%

0.0008

-3

Table 4-Mean Doses of Maternal Buprenorphine and Methadone
Study
Fischer3

Mean Dose of
Buprenorphine (mg)
13.5

Mean Dose of Methadone
(mg)
47.5

Jones4

18.7

79.1

Kakko5

15.4 (± 6.4)

71.3 (± 27.3)

The included studies required a maternal history of opioid dependence as defined by the
DSM-IV. Participants in the study performed by Jones et al were randomized to receive
sublingual buprenorphine 4-24 mg or methadone HCL 20-100 mg, which was titrated based on
each individual’s signs and symptoms of withdrawal. The study began with 30 participants, with
10 women withdrawing, reasons included a medical condition, missed consecutive dosing days
and an elective withdrawal. Similarly, participants in the study performed by Fischer et al were
randomized to receive 8-24 mg of buprenorphine or 40-100 mg of methadone; they began with
18 participants and had 4 withdrawals. Reasons for withdrawal included two participants who
were non compliant with scheduled visits, one stillbirth and one late abortion. Kakko et al
performed a case series, therefore retrospectively analyzed 39 pregnant women who were
managed using buprenorphine therapy and 26 pregnant women who were managed using
methadone therapy.
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Co-morbid drug use was a common external factor in all three studies. Kakko et al noted
that 15 out of 47 participants in the buprenorphine group utilized illicit substances (either opiates
or cannibis) and 17 of the 35 participants receiving methadone did. Fischer et al reported at 14
weeks 66% of mothers were positive for opiates, 48% were positive for cocaine and 16% were
positive for benzodiazepines; however between 36-38 weeks all participants were opioid
positive, but negative for cocaine and benzodiazepines. Jones et al reported of those treated with
buprenorphine 16.7% tested positive for opiates, 15.2% were positive for cocaine and 2.5% were
positive for benzodiazepines at the time of birth. Similarly, of those treated with morphine
15.6% tested positive for opiates, 11.2% were positive cocaine, 0.4% were positive for
benzodiazepines and 7.5% were positive for marijuana.
DISCUSSION
Buprenorphine is FDA approved for the treatment of opiate dependence by preventing
symptoms of withdrawal. It is a partial agonist at the mu-opioid receptor and an antagonist at the
kappa-opioid receptor and is a Schedule III narcotic4. It is available in two formulations;
Suboxone, which contains buprenorphine HCL and naloxone HCL and Subutex, which contain
only buprenorphine HCL. Currently buprenorphine is classified under pregnancy category C and
is indicated during pregnancy only if the benefit justifies the potential risk to the fetus4. Caution
must be used when taking buprenorphine, as respiratory depression and death are potential
adverse effects4.
The study by Kakko et al appeared to show a significant relationship between maternal
buprenorphine use and a decrease in NAS symptoms (p=0.0008). While these findings are
clinically significant, one must use caution when interpreting these results due to the nature of
the study (case series). The two RCTs reviewed (Fischer et al and Jones et al) did not show a
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clinically significant correlation between maternal buprenorphine use and a decrease in NAS
symptoms. Each of the studies included did have limitations. The study performed by Kakko et
al was limited as it was a case series, the study was non-randomized, duration of previous drug
abuse was unknown and NAS scoring and assessments were not blind. While the study by Jones
et al was a RCT, it also had its limitations. The study included only 30 participants with 10
withdrawals and women were not enrolled into the study until 16 weeks gestational age therefore
generalizations cannot be made regarding neonates conceived during already established
maintenance therapy. Fischer et al similarly only had 18 participants with 4 withdrawals and
concurrent tobacco use may have affected outcomes. All of the studies were limited by illicit
drug use.
CONCLUSION
The studies reviewed demonstrate that maternal buprenorphine use during pregnancy is
not effective in reducing signs and symptoms of NAS when compared to methadone. While
Kakko et al did find a significant relationship these findings were limited due to the nature of the
study (case series), the results would have been more significant if it had been a RCT. The two
RCTs included did not find a significant correlation between maternal buprenorphine use and a
reduction in NAS symptoms. Future studies are warranted to evaluate the efficacy of
buprenorphine and NAS. Efforts should be made to reduce outside influences such as illicit drug
use and tobacco use. Larger sample sizes are needed and ideally treatment with either
buprenorphine or methadone should be started prior to conception. Additionally, efforts should
also be made to standardize dosing of buprenorphine and methadone among participants.
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